{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:31:22Z","timestamp":1772818282376,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"DOI":"10.7759\/cureus.104763","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:22:39Z","timestamp":1772796159000},"source":"Crossref","is-referenced-by-count":0,"title":["Empowering Patients in Clinical Research: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Pooja","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Bagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Bondia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapna Rohit","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.594614","article-title":"Clinical trials in cardiovascular medicine in an era of marginal benefit, bias, and hyperbole","volume":"112","author":"Loscalzo J","year":"2005","unstructured":"Loscalzo J. Clinical trials in cardiovascular medicine in an era of marginal benefit, bias, and hyperbole. Circulation. 2005, 112:3026-9. 10.1161\/CIRCULATIONAHA.105.594614","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21876\/hsjhci.v14.2024.e1520","article-title":"The importance of clinical trial protocols","volume":"14","author":"De Moraes Silva MA","year":"2024","unstructured":"De Moraes Silva MA. The importance of clinical trial protocols. HSJ. 2024, 14:e1520. 10.21876\/hsjhci.v14.2024.e1520","journal-title":"HSJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.02.012","article-title":"Patient-centeredness in the design of clinical trials","volume":"17","author":"Mullins CD","year":"2014","unstructured":"Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. Value Health. 2014, 17:471-5. 10.1016\/j.jval.2014.02.012","journal-title":"Value Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1740774518755055","article-title":"Patient engagement in clinical trials: the Clinical Trials Transformation Initiative's leadership from theory to practical implementation","volume":"15","author":"Patrick-Lake B","year":"2018","unstructured":"Patrick-Lake B. Patient engagement in clinical trials: the Clinical Trials Transformation Initiative's leadership from theory to practical implementation. Clin Trials. 2018, 15:19-22. 10.1177\/1740774518755055","journal-title":"Clin Trials"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1574887114666190808142339","article-title":"Patients driving the clinical trial designs - democracy in clinical research","volume":"14","author":"Bhardwaj P","year":"2019","unstructured":"Bhardwaj P, Kumar J, Yadav RK. Patients driving the clinical trial designs - democracy in clinical research. Rev Recent Clin Trials. 2019, 14:237-46. 10.2174\/1574887114666190808142339","journal-title":"Rev Recent Clin Trials"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2168479019849875","article-title":"A novel collaborative approach to building better clinical trials: new insights from a patient engagement workshop to propel patient-centricity forward","author":"Gregg A","year":"2019","unstructured":"Gregg A, Getz N, Benger J, Anderson A. A novel collaborative approach to building better clinical trials: new insights from a patient engagement workshop to propel patient-centricity forward. Ther Innov Regul Sci. 2019, 10.1177\/2168479019849875","journal-title":"Ther Innov Regul Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-018-0784-z","article-title":"Engaging patients to improve quality of care: a systematic review","volume":"13","author":"Bombard Y","year":"2018","unstructured":"Bombard Y, Baker GR, Orlando E, et al.. Engaging patients to improve quality of care: a systematic review. Implement Sci. 2018, 13:98. 10.1186\/s13012-018-0784-z","journal-title":"Implement Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.159936","article-title":"Patient centric approach for clinical trials: current trend and new opportunities","volume":"6","author":"Sharma NS","year":"2015","unstructured":"Sharma NS. Patient centric approach for clinical trials: current trend and new opportunities. Perspect Clin Res. 2015, 6:134-8. 10.4103\/2229-3485.159936","journal-title":"Perspect Clin Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-172","article-title":"Could digital patient communities be the launch pad for patient-centric trial design?","volume":"15","author":"Wicks P","year":"2014","unstructured":"Wicks P. Could digital patient communities be the launch pad for patient-centric trial design?. Trials. 2014, 15:172. 10.1186\/1745-6215-15-172","journal-title":"Trials"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06905-6","article-title":"Commentary: an industry perspective on the importance of incorporating participant voice before, during, and after clinical trials","volume":"23","author":"Goodson N","year":"2022","unstructured":"Goodson N, Wicks P, Farina C. Commentary: an industry perspective on the importance of incorporating participant voice before, during, and after clinical trials. Trials. 2022, 23:966. 10.1186\/s13063-022-06905-6","journal-title":"Trials"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15162.1","article-title":"How to incorporate patient and public perspectives into the design and conduct of research","volume":"7","author":"Hoddinott P","year":"2018","unstructured":"Hoddinott P, Pollock A, O'Cathain A, et al.. How to incorporate patient and public perspectives into the design and conduct of research. F1000Res. 2018, 7:752. 10.12688\/f1000research.15162.1","journal-title":"F1000Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.10.016","article-title":"Bringing patient and caregivers voices to the clinical trial chorus: a report from the BMT CTN Patient and Caregiver Advocacy Task Force","volume":"29","author":"Vasu S","year":"2023","unstructured":"Vasu S, Holtan SG, Shimamura A, et al.. Bringing patient and caregivers voices to the clinical trial chorus: a report from the BMT CTN Patient and Caregiver Advocacy Task Force. Transplant Cell Ther. 2023, 29:5-9. 10.1016\/j.jtct.2022.10.016","journal-title":"Transplant Cell Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3606","article-title":"Incorporating patient and caregiver experiences into cardiovascular clinical trial design","volume":"2","author":"Collins SP","year":"2017","unstructured":"Collins SP, Levy PD, Holl JL, et al.. Incorporating patient and caregiver experiences into cardiovascular clinical trial design. JAMA Cardiol. 2017, 2:1263-9. 10.1001\/jamacardio.2017.3606","journal-title":"JAMA Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00458-4","article-title":"Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions","volume":"37","author":"Faulkner SD","year":"2023","unstructured":"Faulkner SD, Somers F, Boudes M, Nafria B, Robinson P. Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions. Pharmaceut Med. 2023, 37:129-38. 10.1007\/s40290-022-00458-4","journal-title":"Pharmaceut Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00217-0","article-title":"Development and application of a patient group engagement prioritization tool for use in medical product development","volume":"55","author":"Perry B","year":"2021","unstructured":"Perry B, Dombeck C, Smalley JB, et al.. Development and application of a patient group engagement prioritization tool for use in medical product development. Ther Innov Regul Sci. 2021, 55:324-35. 10.1007\/s43441-020-00217-0","journal-title":"Ther Innov Regul Sci"},{"key":"ref16","unstructured":"Cochrane helps launch new WHO guidance on best practices for clinical trials. (2024). https.\/\/www.cochrane.org\/news\/cochrane-helps-launch-new-who-guidance-best-practices-clinical-trials."},{"key":"ref17","unstructured":"World Health Organization. Guidance for best practices for clinical trials. (2024). https.\/\/www.who.int\/publications\/i\/item\/9789240097711."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae267","article-title":"Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure","volume":"191","author":"Pattinson R","year":"2024","unstructured":"Pattinson R, Trialonis-Suthakharan N, Pickles T, Austin J, FitzGerald A, Augustin M, Bundy C. Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. Br J Dermatol. 2024, 191:936-48. 10.1093\/bjd\/ljae267","journal-title":"Br J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-016-0749-2","article-title":"The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease","volume":"18","author":"Johnston A","year":"2016","unstructured":"Johnston A, Jones WS, Hernandez AF. The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease. Curr Cardiol Rep. 2016, 18:81. 10.1007\/s11886-016-0749-2","journal-title":"Curr Cardiol Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000890","article-title":"Rare disease patients in India are rarely involved in international orphan drug trials","volume":"2","author":"Chakraborty M","year":"2022","unstructured":"Chakraborty M, Choudhury MC, Chakraborty I, Saberwal G. Rare disease patients in India are rarely involved in international orphan drug trials. PLOS Glob Public Health. 2022, 2:e0000890. 10.1371\/journal.pgph.0000890","journal-title":"PLOS Glob Public Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58454","article-title":"Patient Advocates for Clinical Research (PACER): a step toward ethical, relevant, and truly participatory clinical research in India","volume":"16","author":"Bagai P","year":"2024","unstructured":"Bagai P, Sharma P, Ansari A, et al.. Patient Advocates for Clinical Research (PACER): a step toward ethical, relevant, and truly participatory clinical research in India. Cureus. 2024, 16:e58454. 10.7759\/cureus.58454","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068666","article-title":"PARTAKE survey of public knowledge and perceptions of clinical research in India","volume":"8","author":"Burt T","year":"2013","unstructured":"Burt T, Dhillon S, Sharma P, et al.. PARTAKE survey of public knowledge and perceptions of clinical research in India. PLoS One. 2013, 8:e68666. 10.1371\/journal.pone.0068666","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/jcpc.jcpc_27_23","article-title":"A cross-sectional survey to assess awareness and perception to clinical research: unbox research","volume":"12","author":"Sharma P","year":"2023","unstructured":"Sharma P, Aggarwal R, Mittal N, et al.. A cross-sectional survey to assess awareness and perception to clinical research: unbox research. J Clin Prev Cardiol. 2023, 12:118-23. 10.4103\/jcpc.jcpc_27_23","journal-title":"J Clin Prev Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_3035_22","article-title":"Attitude and perception toward clinical trials in India among patients and patient bystanders visiting the Indian Ophthalmology Clinical Trial Network: a multi-centric, cross-sectional survey","volume":"71","author":"Pillai GS","year":"2023","unstructured":"Pillai GS, Sheeba CS, Barman M, et al.. Attitude and perception toward clinical trials in India among patients and patient bystanders visiting the Indian Ophthalmology Clinical Trial Network: a multi-centric, cross-sectional survey. Indian J Ophthalmol. 2023, 71:3335-42. 10.4103\/IJO.IJO_3035_22","journal-title":"Indian J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.76283","article-title":"Patient advocacy groups: need and opportunity in India","volume":"2","author":"Shah K","year":"2011","unstructured":"Shah K, Garg S. Patient advocacy groups: need and opportunity in India. Perspect Clin Res. 2011, 2:4-7. 10.4103\/2229-3485.76283","journal-title":"Perspect Clin Res"},{"key":"ref26","article-title":"Clinical Trials Industry in India: A Systematic Review","author":"Mondal S","year":"2015","unstructured":"Mondal S, Abrol D. Clinical Trials Industry in India: A Systematic Review. Institute for Studies in Industrial Development, New Delhi, India; 2015."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber R","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018, 9:353-67. 10.2147\/PROM.S156279","journal-title":"Patient Relat Outcome Meas"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.08.005","article-title":"Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences","volume":"64","author":"Murad MH","year":"2011","unstructured":"Murad MH, Shah ND, Van Houten HK, et al.. Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. J Clin Epidemiol. 2011, 64:743-8. 10.1016\/j.jclinepi.2010.08.005","journal-title":"J Clin Epidemiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1864","article-title":"Patients' preferences within randomised trials: systematic review and patient level meta-analysis","volume":"337","author":"Preference Collaborative Review Group","year":"2008","unstructured":"Preference Collaborative Review Group. Patients' preferences within randomised trials: systematic review and patient level meta-analysis. BMJ. 2008, 337:a1864. 10.1136\/bmj.a1864","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00082","article-title":"Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs","volume":"6","author":"Cook NS","year":"2019","unstructured":"Cook NS, Cave J, Holtorf AP. Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs. Front Med (Lausanne). 2019, 6:82. 10.3389\/fmed.2019.00082","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.05.008","article-title":"Patient preferences to value health outcomes in rheumatology clinical trials: report from the OMERACT special interest group","volume":"51","author":"Thomas M","year":"2021","unstructured":"Thomas M, Fraenkel L, Boonen A, et al.. Patient preferences to value health outcomes in rheumatology clinical trials: report from the OMERACT special interest group. Semin Arthritis Rheum. 2021, 51:919-24. 10.1016\/j.semarthrit.2021.05.008","journal-title":"Semin Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay CC","year":"2008","unstructured":"Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008, 26:1355-63. 10.1200\/JCO.2007.13.3439","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e81","article-title":"A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer","volume":"29","author":"Wilson MK","year":"2018","unstructured":"Wilson MK, Mercieca-Bebber R, Friedlander M. A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol. 2018, 29:e81. 10.3802\/jgo.2018.29.e81","journal-title":"J Gynecol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-008-9379-5","article-title":"Prospects and challenges in using patient-reported outcomes in clinical practice","volume":"17","author":"Fung CH","year":"2008","unstructured":"Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008, 17:1297-302. 10.1007\/s11136-008-9379-5","journal-title":"Qual Life Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients' decision making on participation in clinical trials","volume":"26","author":"Albrecht TL","year":"2008","unstructured":"Albrecht TL, Eggly SS, Gleason ME, et al.. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol. 2008, 26:2666-73. 10.1200\/JCO.2007.14.8114","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_147_16","article-title":"Informed consent process: a step further towards making it meaningful!","volume":"8","author":"Kadam RA","year":"2017","unstructured":"Kadam RA. Informed consent process: a step further towards making it meaningful!. Perspect Clin Res. 2017, 8:107-12. 10.4103\/picr.PICR_147_16","journal-title":"Perspect Clin Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07159-6","article-title":"Complex and alternate consent pathways in clinical trials: methodological and ethical challenges encountered by underserved groups and a call to action","volume":"24","author":"Russell AM","year":"2023","unstructured":"Russell AM, Shepherd V, Woolfall K, et al.. Complex and alternate consent pathways in clinical trials: methodological and ethical challenges encountered by underserved groups and a call to action. Trials. 2023, 24:151. 10.1186\/s13063-023-07159-6","journal-title":"Trials"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16636844","article-title":"A patient-centered approach to informed consent: results from a survey and randomized trial","volume":"36","author":"Krishnamurti T","year":"2016","unstructured":"Krishnamurti T, Argo N. A patient-centered approach to informed consent: results from a survey and randomized trial. Med Decis Making. 2016, 36:726-40. 10.1177\/0272989X16636844","journal-title":"Med Decis Making"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31747","article-title":"Social media and clinical trials: the pros and cons gain context when the patient is at the center","volume":"124","author":"Thompson MA","year":"2018","unstructured":"Thompson MA, O'Regan RM. Social media and clinical trials: the pros and cons gain context when the patient is at the center. Cancer. 2018, 124:4618-21. 10.1002\/cncr.31747","journal-title":"Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-023-00461-3","article-title":"Considerations for effective communication of medical information","volume":"37","author":"Power EG","year":"2023","unstructured":"Power EG. Considerations for effective communication of medical information. Pharmaceut Med. 2023, 37:97-101. 10.1007\/s40290-023-00461-3","journal-title":"Pharmaceut Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-7625.2004.00281.x","article-title":"A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance","volume":"7","author":"Stevenson FA","year":"2004","unstructured":"Stevenson FA, Cox K, Britten N, Dundar Y. A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance. Health Expect. 2004, 7:235-45. 10.1111\/j.1369-7625.2004.00281.x","journal-title":"Health Expect"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e101","article-title":"Social media in clinical trials","volume":"34","author":"Thompson MA","year":"2014","unstructured":"Thompson MA. Social media in clinical trials. Am Soc Clin Oncol Educ Book. 2014, 34:e101-5. 10.14694\/EdBook_AM.2014.34.e101","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref43","unstructured":"Acurian. The global enrollment & retention specialist. (2024). https.\/\/trialmed.com\/."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31748","article-title":"Protecting clinical trial participants and study integrity in the age of social media","volume":"124","author":"Lynch HF","year":"2018","unstructured":"Lynch HF, Largent EA, Joffe S, DeMichele AM. Protecting clinical trial participants and study integrity in the age of social media. Cancer. 2018, 124:4610-7. 10.1002\/cncr.31748","journal-title":"Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00811-8","article-title":"Establishing a framework for the use of social media in pharmacovigilance in Europe","volume":"42","author":"Brosch S","year":"2019","unstructured":"Brosch S, de Ferran AM, Newbould V, Farkas D, Lengsavath M, Tregunno P. Establishing a framework for the use of social media in pharmacovigilance in Europe. Drug Saf. 2019, 42:921-30. 10.1007\/s40264-019-00811-8","journal-title":"Drug Saf"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0491-0","article-title":"Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts","volume":"40","author":"Pierce CE","year":"2017","unstructured":"Pierce CE, Bouri K, Pamer C, et al.. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts. Drug Saf. 2017, 40:317-31. 10.1007\/s40264-016-0491-0","journal-title":"Drug Saf"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0008-2020","article-title":"Getting the word out: how to talk to the public about your research","volume":"16","author":"Orritt R","year":"2020","unstructured":"Orritt R, Powell P. Getting the word out: how to talk to the public about your research. Breathe (Sheff). 2020, 16:200008. 10.1183\/20734735.0008-2020","journal-title":"Breathe (Sheff)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.01.011","article-title":"Decentralized clinical trials: the future of medical product development?","volume":"6","author":"Van Norman GA","year":"2021","unstructured":"Van Norman GA. Decentralized clinical trials: the future of medical product development?. JACC Basic Transl Sci. 2021, 6:384-7. 10.1016\/j.jacbts.2021.01.011","journal-title":"JACC Basic Transl Sci"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00052-3","article-title":"Decentralised clinical trials: ethical opportunities and challenges","volume":"5","author":"Vayena E","year":"2023","unstructured":"Vayena E, Blasimme A, Sugarman J. Decentralised clinical trials: ethical opportunities and challenges. Lancet Digit Health. 2023, 5:e390-4. 10.1016\/S2589-7500(23)00052-3","journal-title":"Lancet Digit Health"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.597","article-title":"Decentralized clinical trials in the trial innovation network: value, strategies, and lessons learned","volume":"7","author":"Hanley DF Jr","year":"2023","unstructured":"Hanley DF Jr, Bernard GR, Wilkins CH, et al.. Decentralized clinical trials in the trial innovation network: value, strategies, and lessons learned. J Clin Transl Sci. 2023, 7:e170. 10.1017\/cts.2023.597","journal-title":"J Clin Transl Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64042","article-title":"Emphasizing patient-centricity through a tailored training program to empower patients, advocates, and ethics committees in good clinical practice","volume":"16","author":"Bagai P","year":"2024","unstructured":"Bagai P, Sharma P, Ansari A, et al.. Emphasizing patient-centricity through a tailored training program to empower patients, advocates, and ethics committees in good clinical practice. Cureus. 2024, 16:e64042. 10.7759\/cureus.64042","journal-title":"Cureus"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4103\/jcpc.jcpc_18_24","article-title":"Perspective of patient advocacy groups on clinical research and outcomes of their involvement","volume":"13","author":"Bagai P","year":"2024","unstructured":"Bagai P, Sharma P, Ansari A, et al.. Perspective of patient advocacy groups on clinical research and outcomes of their involvement. J Clin Prev Cardiol. 2024, 13:54-62. 10.4103\/jcpc.jcpc_18_24","journal-title":"J Clin Prev Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_11_01_04","article-title":"The Clinical Trials Transformation Initiative (CTTI)","volume":"47","author":"Grignolo A","year":"2011","unstructured":"Grignolo A. The Clinical Trials Transformation Initiative (CTTI). Ann Ist Super Sanita. 2011, 47:14-8. 10.4415\/ANN_11_01_04","journal-title":"Ann Ist Super Sanita"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00230","article-title":"EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes","volume":"5","author":"Haerry D","year":"2018","unstructured":"Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, See W. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med (Lausanne). 2018, 5:230. 10.3389\/fmed.2018.00230","journal-title":"Front Med (Lausanne)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0148-3","article-title":"Artificial intelligence and machine learning in clinical development: a translational perspective","volume":"2","author":"Shah P","year":"2019","unstructured":"Shah P, Kendall F, Khozin S, et al.. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med. 2019, 2:69. 10.1038\/s41746-019-0148-3","journal-title":"NPJ Digit Med"},{"key":"ref56","article-title":"Patient centricity: design and conduct of clinical trials in orphan diseases: third of three sets of expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development","volume":"20","author":"Busner J","year":"2023","unstructured":"Busner J, Pandina G, Day S, Mahableshwarkar A, Kempf L, Sheean M, Dunn J. Patient centricity: design and conduct of clinical trials in orphan diseases: third of three sets of expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development. Innov Clin Neurosci. 2023, 20:25-31.","journal-title":"Innov Clin Neurosci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01400-0","article-title":"To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases","volume":"15","author":"Lanar S","year":"2020","unstructured":"Lanar S, Acquadro C, Seaton J, Savre I, Arnould B. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases. Orphanet J Rare Dis. 2020, 15:134. 10.1186\/s13023-020-01400-0","journal-title":"Orphanet J Rare Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432236-empowering-patients-in-clinical-research-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:22:41Z","timestamp":1772796161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432236-empowering-patients-in-clinical-research-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.104763","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}